Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...
PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...